TMCnet News
Vicor Technologies' Chief Medical Officer to Present Abstract on Hypovolemia Study Results at the AABB 2010 Annual MeetingBOCA RATON, FL, Jul 28, 2010 (MARKETWIRE via COMTEX) -- David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Vicor Chief Medical Officer Dr. Daniel Weiss will present an abstract of the results of a pilot study to test the ability of Vicor's PD2i(R) nonlinear algorithm to detect acute hypovolemia at the AABB 2010 Annual Meeting. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i(R) nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention. Dr. Weiss will present Mild Hemorrhage Results in Observable Changes in Heart Rate Variability (S106-040B) on October 12, 2010 at 3:15pm in room 339/340, during the session entitled Donor Recruitment, Retention and Adverse Events: Hemoglobin and Iron. The AABB Annual Meeting & CTTXPO 2010 will be held at the Baltimore Convention Center on October 9-12, 2010. "We're honored to have Dr. Weiss's abstract of our hypovolemia study selected for presentation before this prestigious group. We believe the results achieved by the PD2i(R) in this small pilot study suggest the prospect of incorporating the PD2i(R) nonlinear algorithm into a noninvasive diagnostic for use in identifying patients who are bleeding internally. We hope that having the opportunity to share these results with those active in the field of transfusion medicine and cellular technologies worldwide will further opportunities to advance study of the PD2i(R) as a noninvasive diagnostic to detect acute hypovolemia, and further our commercialization efforts for the PD2i(R)," stated Mr. Fater. The study on which the abstract is based was conducted in cooperation with the University of Mississippi Medical Center and Mississippi Blood Services on December 12, 2009 in Smithdale, MS. The goal of the study was to test the ability of Vicor's PD2i(R) nonlinear algorithm to identify acute hypovolemia in blood donors as a preliminary step toward ascertaining whether it could be a useful noninvasive diagnostic for detecting blood loss from internal bleeding. All 18 participants in the pilot study were tested prior to donation to determine a baseline PD2i(R) value, and re-tested during and after collection. The average PD2i(R) value of participants prior to donation was 2.60; the average PD2i(R) value following donation was 1.80. With a P value of 0.001, the study results are highly statistically significant; this indicates a better than 99% probability that the results were not achieved randomly. The AABB is an international, not-for-profit association representing individuals and institutions involved in the field of transfusion medicine and cellular therapies. The association is committed to improving health by developing and delivering standards, accreditation and educational programs that focus on optimizing patient and donor care and safety. AABB membership consists of nearly 2,000 institutions and 8,000 individuals, including physicians, nurses, scientists, researchers, administrators, medical technologists and other health care providers. Members are located in more than 80 countries. About Vicor Technologies, Inc. Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i(R)). The PD2i(R) nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations. The PD2i Analyzer(TM), which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer(TM) are able to receive reimbursement under existing CPT codes. The PD2i VS(TM) (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA(TM) (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure. Vicor anticipates developing additional applications utilizing the PD2i(R) nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com. Disclaimer The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense, the U.S. Government, or the AABB of the information, products or services contained therein. Caution Regarding Forward-Looking Statements Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer(TM); our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA(TM)(Cardiac Analyzer) for risk stratifying congestive heart failure patients at elevated risk of cardiac mortality and our ability to obtain marketing clearance from the FDA for the PD2i VS(TM) (Vital Sign) for military and civilian applications; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ. Release 10-12 CORPORATE CONTACT David H. Fater Vicor Technologies, Inc. 561.995.7313 [email protected] INVESTOR CONTACT Richard Moyer Cameron Associates 212.554.5466 [email protected] MEDIA CONTACT Robin Schoen Robin Schoen Public Relations 215.504.2122 [email protected] SOURCE: Vicor Technologies, Inc. mailto:[email protected] mailto:[email protected] mailto:[email protected] |